Those results showed that RFP-expressing CCR2(+) monocytes were significantly increased in the group treated with anti-IL-4 and anti-IL-13 on day 3 after ischemic stroke compared with the IgG1 (vehicle)-treated group (Fig. 5c). The gene discussed is IL13; the disease is ischemic stroke.